Oncologic and Surgical Outcomes After Short-Course Neoadjuvant CAPOX Plus Bevacizumab in High-Risk Colorectal Liver Metastases

A two-cycle, short-course regimen of CAPOX plus bevacizumab proved both effective and safe in high-risk CRLM, achieving meaningful biochemical, radiologic, and pathologic responses with acceptable toxicity. This abbreviated approach allowed delivery of neoadjuvant therapy while limiting cumulative treatment-related toxicity, supporting its feasibility as a neoadjuvant strategy in selected high-risk CRLM patients.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-02-05
DOI
https://doi.org/10.3390/cancers18030521
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Oncologic and Surgical Outcomes After Short-Course Neoadjuvant CAPOX Plus Bevacizumab in High-Risk Colorectal Liver Metastases

Birgit Gruenberger, Jonas Santol, Mariel Gramberger, Yawen Dong et al.
Cancers
Hepatocellular Carcinoma Treatment and Prognosis
article

Oncologic and Surgical Outcomes After Short-Course Neoadjuvant CAPOX Plus Bevacizumab in High-Risk Colorectal Liver Metastases

Birgit Gruenberger, Jonas Santol, Mariel Gramberger, Yawen Dong, T. Hoblaj, Rebecca Thonhauser, Madita M Tschoegl, Francesca Notte, Edanur Cenan, Rosemarie Valenta, Thomas Gruenberger, Florian Lehner, Mohammed Salem
article en

Abstract

A two-cycle, short-course regimen of CAPOX plus bevacizumab proved both effective and safe in high-risk CRLM, achieving meaningful biochemical, radiologic, and pathologic responses with acceptable toxicity. This abbreviated approach allowed delivery of neoadjuvant therapy while limiting cumulative treatment-related toxicity, supporting its feasibility as a neoadjuvant strategy in selected high-risk CRLM patients.

CancersVol. 18(3)
Sigmund Freud Privatuniversität Wien (AT), Fachhochschule Wiener Neustadt (AT), SBA Research (AT)
Good health and well-being
Openalex Percentile: Top 64%
Hepatocellular Carcinoma Treatment and Prognosis
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Oncologic and Surgical Outcomes After Short-Course Neoadjuvant CAPOX Plus Bevacizumab in High-Risk Colorectal Liver Metastases — Birgit Gruenberger, Jonas Santol, et al. · Cancers (2026) | TGRS Research Map | TGRS